logo BDSP

Base documentaire


  1. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate.

    Article - En anglais

    Objective

    Methotrexate (MTX) is being used increasingly to treat rheumatoid arthritis (RA).

    Pneumonitis is a serious side effect of MTX therapy (P-MTX).

    Our aim was to determine in patients with RA the incidence and prevalence of P-MTX in Western Australia and identify risk factors for the development of this adverse reaction.

    Methods

    Patients with P-MTX were identifed by (a) direct communication with rheumatologists in Western Australia, (b) use of a computerized clinical database, (c) questionnaire inquiry of all other rheumatologists in Australia.

    Mots-clés Pascal : Polyarthrite rhumatoïde, Homme, Traitement, Méthotrexate, Chimiothérapie, Toxicité, Pneumonie, Epidémiologie, Australie, Océanie, Chronique, Système ostéoarticulaire pathologie, Rhumatisme inflammatoire, Immunopathologie, Maladie autoimmune, Immunomodulateur, Antirhumatismal, Appareil respiratoire pathologie, Poumon pathologie

    Mots-clés Pascal anglais : Rheumatoid arthritis, Human, Treatment, Chemotherapy, Toxicity, Pneumonia, Epidemiology, Australia, Oceania, Chronic, Diseases of the osteoarticular system, Inflammatory joint disease, Immunopathology, Autoimmune disease, Immunomodulator, Antirheumatic agent, Respiratory disease, Lung disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 94-0152272

    Code Inist : 002B02U07. Création : 199406.